UCSF UC San Francisco Previously Published Works

Title

Lung Transplantation for Patients With COVID-19

Permalink

https://escholarship.org/uc/item/4nv2n0s0

Journal CHEST Journal, 161(1)

ISSN

0012-3692

Authors

King, Christopher S Mannem, Hannah Kukreja, Jasleen <u>et al.</u>

Publication Date

2022

DOI

10.1016/j.chest.2021.08.041

Peer reviewed



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

1 2

3

4

5

6

8

9

10

11

15

16

17

18

19

20

21

22

23

24 25

26

27

28

29

30

31

32

33

34

35

36

37 38

39 40

41

42

43

44 45

46

Q9 7

Patients

How I Do It

📚 CHEST

57 58 59 60 61 62 63 64 65

66

67

68

69

70

56

12 Christopher S. King, MD; Hannah Mannem, MD; Jasleen Kukreja, MD; Shambhu Aryal, MD; Daniel Tang, MD; Q10 13 Q1 Q2 Jonathan P. Singer, MD; Ankit Bharat, MD; Juergen Behr, MD; and Steven D. Nathan, MD 14

Lung Transplantation of COVID-19

71 The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. 72 Some patients develop COVID-related acute respiratory distress syndrome (CARDS) and 73 cannot be liberated from mechanical ventilation. Others may develop post-COVID fibrosis, 74 resulting in substantial disability and need for long-term supplemental oxygen. In both of these $\frac{1}{75}$ situations, treatment teams often inquire about the possibility of lung transplantation. In fact, 76 lung transplantation has been successfully employed for both CARDS and post-COVID fibrosis 77 in a limited number of patients worldwide. Lung transplantation after COVID infection presents 78 a number of unique challenges that transplant programs must consider. In those with severe 79 CARDS, the inability to conduct proper psychosocial evaluation and pretransplantation educa- 80 tion, marked deconditioning from critical illness, and infectious concerns regarding viral reac-⁸¹ tivation are major hurdles. In those with post-COVID fibrosis, our limited knowledge about the 82 natural history of recovery after COVID-19 infection is problematic. Increased knowledge of the 83 likelihood and degree of recovery after COVID-19 acute lung injury is essential for appropriate 84 85 decision-making with regard to transplantation. Transplant physicians must weigh the risks and 86 benefits of lung transplantation differently in a post-COVID fibrosis patient who is likely to 87 remain stable or gradually improve in comparison with a patient with a known progressive 88 fibrosing interstitial lung disease (fILD). Clearly lung transplantation can be a life-saving 80 therapeutic option for some patients with severe lung injury from COVID-19 infection. In this 90 review, we discuss how lung transplant providers from a number of experienced centers 91 CHEST 2021; ■(■):■-■ 92 approach lung transplantation for CARDS or post-COVID fibrosis. 93

Hospital, Falls Church, VA.

Elsevier Inc. All rights reserved.

DOI: https://doi.org/10.1016/j.chest.2021.08.041

king@inova.org

KEY WORDS: ARDS; COVID-19; lung transplantation; pulmonary fibrosis

COVID-19 has infected over 150 million people worldwide since the start of the pandemic.1 Critical disease, characterized by respiratory failure, shock, and multi-organ system failure, occurs in approximately 5% of infections, which equates to

Falls Church, VA; Lung Transplantation (J. P. Singer), University of 102

Behr), University Hospital, LMU Munich, Germany; and the Advanced 104

Lung Disease and Transplant Program (S. D. Nathan), Inova Fairfax 105

CORRESPONDENCE TO: Christopher King, MD; email: Christopher. 04

Copyright © 2021 American College of Chest Physicians. Published by

California, San Francisco, CA; Lung Transplantation (A. Bharat),

Northwestern Medicine, Chicago, IL; the Department of Medicine V (J.

94

95

96

97

98

101

103

106

108

109

110

47 ABBREVIATIONS: 6MWT = 6-minute walk test; AKI = acute kidney injury; CARDS = COVID-related acute respiratory distress syndrome; 48 ECMO = extracorporeal membrane oxygenation; fILD = fibrosing 49 interstitial lung disease; ILD = interstitial lung disease; LTx = lung transplantation; PFT = pulmonary function testing; rt-PCR = real-time 50 polymerase chain reaction 51

AFFILIATIONS: From the Advanced Lung Disease and Transplant Q3 52 Program (C. S. King), Inova Fairfax Hospital, Falls Church, VA; Lung 53 Transplantation (H. Mannem), University of Virginia, Charlottesville, VA; Lung Transplantation (J. Kukreja), University of California, San 54 Francisco, CA; Advanced Lung Disease and Transplant Program (S. 55 Aryal) and Cardiothoracic Surgery (D. Tang), Inova Fairfax Hospital,

⁹⁹ 100

111 approximately 7.5 million individuals struck down by 112 critical disease thus far.² Death rates amongst patients 113 with critical COVID-19 infections are high, at more than 114 30% in most series.³ A proportion of survivors from 115 COVID-19 acute lung injury are left with residual lung 116 disease, resulting in the need for supplemental oxygen 117 and impaired mobility.⁴ The massive influx of critically 118 ill patients has had profound impacts on health care 119 systems throughout the world. The field of lung 120 transplantation (LTx) has not been spared from this and 121 122 has been affected in a myriad of ways as well. Many of 123 the victims of critical COVID-19 lung injury are 124 relatively young and previously healthy individuals with 125 single-organ dysfunction, so LTx is often considered as a 126 salvage therapeutic option. Transplant centers have seen 127 a large uptick in the number of requests for evaluation 128 for LTx; often involving emotionally and intellectually 129 challenging situations in which patients do not meet 130 traditional criteria for acceptable LTx recipients but have 131 no other path forward to recovery. In this review, we 132 present two very different cases of patients affected by 133 COVID who were referred for LTx evaluation. We will 134 then discuss some common scenarios that can lead to 135 136 referral for LTx evaluation and discuss issues that must 137 be considered when performing transplantation on 138 patients with COVID-19. 139

Case 1

140

141

150

151

152

153

154

155 156

157

158

159

160

161

162

163

2 How I Do It


142 A 62-year-old man presented to the clinic for an LTx 143 evaluation in October 2020, approximately 5 months 144 after initially developing COVID-19. The patient was 145 previously healthy, specifically with no known lung 146 disease, until he was infected with SARS-CoV-2 and 147 required hospitalization. He was treated with remdesivir, 148 149 steroids, and tocilizumab but developed COVID-19

166 acute respiratory distress syndrome (CARDS). Although 167 intubation was avoided, he remained reliant on high-168 flow nasal cannula and noninvasive ventilation, with 169 marked desaturations that limited his mobility. Given 170 dysphagia and marked desaturation, the patient had a 171 tracheostomy and percutaneous gastrostomy tube placed 172 and was discharged to a long-term acute care facility 173 after a 3-month hospitalization. The patient had been 174 decannulated before returning to clinic but remained 175 quite debilitated, having difficulty with activities of daily 176 living and requiring 4 L supplemental oxygen at rest and 177 6 L with ambulation. CT of the lungs (Fig 1B) obtained 178 179 at the time of the clinic visit revealed diffuse ground-180 glass opacities, upper lung peripheral consolidation, and 181 traction bronchiectasis that had progressed from a CT 182 obtained at the time of admission (Fig 1A). Pulmonary 183 function testing showed a moderately severe restrictive 184 defect (FVC, 1.82 L [45%]; FEV1, 1.55L [50%]). He was 185 unable to tolerate the diffusion capacity of the lung for 186 carbon monoxide maneuver. The patient was referred to 187 pulmonary rehabilitation and scheduled for follow-up in 188 clinic in several months to assess for clinical 189 improvement. 190

Case 2

A 37-year-old woman with no significant medical history developed COVID-19 pneumonia with progressive respiratory failure. She was treated with remdesivir, dexamethasone, diuretics, and empiric antibiotics, with no significant improvement. She was intubated and subsequently placed on venous-venous extracorporeal membrane oxygenation (ECMO) approximately 20 days after her initial symptoms. Her hospital course was complicated by ventilator-associated Stenotrophomonas and methicillin-resistant

164 Figure 1 - Case 1: A, Diffuse ground-glass opacities on CT obtained at the time of admission; B, CT chest obtained at initial clinic follow-up 5 months 165 after developing COVID-19 demonstrates diffuse ground-glass opacities, upper lung peripheral consolidation and traction bronchiectasis.





191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

219

220

221 Staphylococcus aureus pneumonia, for which she 222 received appropriate antibiotics. Over time she was 223 weaned off sedation to a point at which she could be 224 awake, interactive, and able to participate in physical 225 therapy. However, her lung mechanics showed no 226 significant improvement, and after 8 weeks she 227 remained on full support from both the ventilator and 228 the ECMO circuit. Her chest CT (Fig 2) showed upper 229 lobe predominant pulmonary fibrosis and traction 230 bronchiectasis along with areas of ground-glass opacities 231 232 throughout.

What Is the Current Status of Lung Transplantation for COVID-19 Lung Injury?

233 234

235

236

261

262

263

264

265

266

267

268

269

270

271 272

273

274

275

Despite the COVID pandemic generating a tremendous 237 number of potential candidates for LTx, as well as 238 239 significant interest and enthusiasm for use of LTx as a 240 salvage option for residual COVID-19 lung disease, the 241 actual number of transplants performed worldwide is 242 fairly small. Although the exact number of transplants is 243 not known, the available data give us some sense of the 244 scope of LTx for COVID-19. A query of the United 245 Network for Organ Sharing showed that as of April 30, 246 2021, only 78 LTxs carrying a recipient diagnosis of 247 COVID-19 had been performed in the United States, 50 248 for CARDS and 28 for COVID fibrosis.⁴ This number is 249 likely lower than the true number of transplants, as the 250 United Network for Organ Sharing implemented 251 252 COVID diagnoses on October 28, 2020, and therefore 253 LTx performed before that date would not be captured 254 unless centers retroactively re-coded prior transplants.⁴ 25506 The European experience seems similar. As of April 23, 256 2021, the Eurotransplant consortium (responsible for 257 organ allocation in Austria, Belgium, Croatia, Germany, 258 Hungary, Luxemburg, the Netherlands, and Slovenia) 259 reported only 21 patients undergoing transplantation for 260




Figure 2 – Case 2: CT chest with upper lobe predominant pulmonary fibrosis and traction bronchiectasis along with areas of ground-glass opacities.

276 a diagnosis of COVID-19 (Personal communication, **Q7**7 Juergen Behr). The relatively small number of LTxs 278 proportional to such a high number of potential 279 recipients is likely multifactorial. Health care systems 280 overwhelmed by the pandemic may not have had 281 adequate resources to provide the intensive support 282 required in recipients. In fact, many transplant programs 283 were placed on hold during the peak of the pandemic. 284 Clinical uncertainty regarding best practices 285 surrounding this new indication for LTx likely also 286 contributed. Finally, many of the referred patients likely 287 had significant relative contraindications to 288 transplantation that precluded their candidacy. Moving 289 forward, it will be essential to review outcomes from the 290 291 cohort of COVID-19 patients who underwent 292 transplantation to ensure their outcomes are comparable 293 to other indications for LTx and to identify predictors of 294 success. 295

How Should One Approach the Outpatient Evaluation for Transplantation of a COVID Fibrosis Patient?

Should COVID-19 Fibrosis Be Approached301Differently From Other Forms of Fibrotic Interstitial302Lung Disease?303

304 Likely the COVID-19 pandemic will affect the 305 management of fibrotic interstitial lung disease (fILD) 306 for years to come. COVID-19 acute lung injury will be 307 added to the differential diagnosis or contributory 308 exposure for all fILD, and assessing for a history of 309 COVID-19 pneumonia will become a requisite standard 310 during history taking. Indeed, we posit that any COVID- 311 19 infection might emerge as a risk factor for the 312 subsequent development of interstitial lung disease 313 (ILD), akin to burn-pit exposures and World Trade 314 Center exposures, which only became evident years 315 316 later. These patients, particularly those more severely 317 affected, are already being referred to ILD and LTx 318 programs. However, the optimal approach in the 319 evaluation and treatment of these patients is yet to be 320 determined. An essential element in the decision to list a 321 patient for LTx is weighing the risk of transplantation 322 vs that of their underlying lung disease. Transplant 323 pulmonologists and surgeons take into consideration 324 their knowledge of the natural history of the patient's 325 lung disease and only advise listing for LTx when doing 326 so is likely to improve longevity and the patient's quality 327 328 of life. The International Society of Heart and Lung 329 Transplantation provided criteria for both referral and 330 listing for LTx in a consensus guideline released in

chestjournal.org

296

297

298

299

2014.⁵ Many of the criteria for ILD could be applied to
COVID-19 fibrosis, because they are meant to apply to
progressive fILD. However, the rate of progression and
the potential for improvement in COVID-19 fibrosis are
largely unknown yet and render application of those
criteria questionable.

What Is the Natural History of, Risk Factors for, and Pathogenesis of COVID-19 Fibrosis?

338

Decisions regarding the appropriateness of LTx for 342 COVID-19 in the outpatient setting hinge on knowledge 343 344 and understanding of the natural history of the disorder, 345 and therefore better insight into the probability of 346 progression or improvement in COVID-19 fibrosis is 347 essential. Unfortunately, data regarding this are limited. 348 The Swiss Covid-19 lung study reported on pulmonary 349 function testing (PFT) and radiographic features 350 4 months after initial symptoms in 113 patients 351 representing the spectrum of COVID-19 disease, 352 including patients with mild or moderate as well as those 353 with severe disease.⁶ Patients with prior severe or critical 354 disease had lower lung volumes than patients with mild 355 356 or moderate disease and had abnormally reduced 357 diffusion capacity, reduced functional capacity, and 358 demonstrated exertional oxygen desaturation. Over 359 50% of patients had mosaic attenuation, reticulations, or 360 architectural distortion on CT scan after severe or 361 critical disease.⁶ Fibrotic changes on chest CT were 362 demonstrated in 35% of patients from a prospective 363 cohort of 114 patients who survived severe COVID-19 364 pneumonia, an additional 27% had interstitial 365 thickening or ground-glass opacification, and 38% had 366 complete radiographic resolution.⁷ Another series 367 reported 3-month follow-up data on a cohort of 62 368 patients who required ICU care for CARDS.8 Of these 369 370 post-CARDS patients, 49% of patients had evidence of 371 reticular lesions, and a further 21% had more distinctive 372 fibrotic patterns. Risk factors for the development of 373 post-COVID fibrosis identified thus far include 374 advanced age, greater severity of illness and longer ICU 375 stay, need for mechanical ventilation, and history of 376 smoking or alcoholism.⁹ The pathogenesis of pulmonary 377 fibrosis after COVID is incompletely understood. It is 378 believed that the virus activates profibrotic pathways 379 through alteration of the renin-angiotensin system 380 balance and activation of growth factors, including 381 382 fibroblast growth factor, epithelial growth factor, and 383 transforming growth factor beta. Additionally, direct 384 cellular injury of alveolar epithelial and endothelial cells 385 and macrophages, inflammation, and damage from

mechanical forces can lead to fibroblast/myofibroblast activation with resultant fibrosis.¹⁰ Likely some patients have a genetic predilection to fibrosis formation after COVID-19 as well, akin to the purported mechanisms in other fILD.

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

Based on the available data and extrapolating from other cause of ARDS, likely the vast majority of patients with COVID-19 fibrosis will improve or remain stable.¹¹ The duration of time that one can expect ongoing recovery remains unclear. Anecdotally, the authors have observed ongoing improvement over the course of many months. However, patients should be closely followed-up because there may be a minority who develop progressive fibrosis, either from post-COVID fibrosis alone or from exacerbation of a previously unrecognized fibrotic lung disease. For example, an estimated 2% to 7% of nonsmokers and 4% to 9% of smokers have interstitial lung abnormalities, with most of these likely going undiagnosed or without consequence in the absence of CT imaging of the chest.¹² How many of such cases are uncovered by an intercurrent COVID-19 infection and whether the existence of these lesions represent a risk factor for a more fibrotic response is uncertain. In such cases, whether COVID is the cause or simply uncovers occult ILD is open to speculation.

How Do the Authors Approach the Evaluation and Management of Post-COVID Fibrosis?

417 The authors' approach to post-COVID fibrosis is very 418 similar to that taken for ILD in general. It starts with a 419 careful assessment for previously unrecognized fibrotic 420 lung disease (Table 1). The history should assess for 421 dyspnea before the development of COVID-19. Patients 422 should be queried about exposures both occupational 423 and otherwise known to be associated with ILD, family 424 history of ILD, and signs, symptoms, or history of 425 426 connective tissue disease. Chest imaging obtained before 427 COVID infection, if available, should be carefully 428 reviewed for signs of ILD. Baseline PFT, chest CT, and 429 6-minute walk test (6MWT) should be obtained. 430 Consideration can be given to obtaining connective-431 tissue disease serologies, particularly if signs or 432 symptoms exist. Some centers advocate reviewing post-433 COVID fibrosis cases at a multidisciplinary pulmonary 434 meeting to get input regarding the optimal diagnostic 435 and therapeutic strategy. Patients with any residual 436 pulmonary sequelae should be referred to pulmonary 437 438 rehabilitation, especially if significant debility exists. 439 Given mounting data on potential benefit, a course of 440 corticosteroids should be considered in patients with

	Considerations Before Transplantation in Outpatients With Post-COVID Fibrosis
1	Assess for evidence of preexisting ILD
	 History: Symptoms before COVID-19 infection, family history of ILD, connective tissue disease history or signs/symptoms, occupational or other exposures associated with chronic hypersensitivity pneumonitis
	Review available chest imaging from before COVID-19 infection
	Consider connective tissue disease testing
	Obtain baseline PFTs, 6MWT, and imaging, and monitor serially
	Consider a trial of corticosteroids
	Consider anti-fibrotic (pirfenidone or nintedanib) if evidence of progression
	Refer for pulmonary rehabilitation
	Transplantation is reserved for severe debility failing to improve with time, medical therapy, and rehabilitation or progressive disease
	5MWT = 6-minute walk test; ILD = interstitial lung disease; PFT = pulmonary function testing
1	radiographic evidence of organizing pneumonia. ^{8,13,14}

on serial follow-up. Licensed anti-fibrotic therapy, either 468 pirfenidone or nintedanib, can be considered in patients 469 demonstrating evidence of progression.¹⁵ Clinical trials 470 to define the role of antifbrotic therapy in CARDS and 471 post-COVID fibrosis are ongoing.¹⁶⁻¹⁹ LTx should be 472 reserved for patients with progressive disease or static 473 disease with substantial disability directly attributable to 474 lung disease. Patients should be screened for anxiety, 475 depression, and posttraumatic stress disorder after their 476 illness, and if identified be referred for proper medical 477 and psychological treatment. In patients with static 478 479 disease, efforts at medical treatment and rehabilitation 480 should be undertaken, and adequate time for recovery 481 should be allowed before entertaining LTx. Where there 482 is uncertainty regarding eventual recovery, evaluation 483 and education about LTx can proceed with the hope that 484 the patient will recover to the point of not requiring a 485 LTx. 486

How Should One Approach the Inpatient Evaluation for Transplant of a COVID Fibrosis Patient?

Inpatient evaluation of COVID-19 patients for LTx
presents a unique set of challenges from that for
outpatients and requires different considerations. In the
authors' collective experience, two general phenotypes of

patients are referred for LTx evaluation for COVID. The 496 first are CARDS patients on either invasive mechanical 498 ventilation or ECMO and failing to improve. The second 499 phenotype are patients that survived their initial COVID 500 infection, but remain dependent on a significant amount 501 of supplemental oxygen, which precludes safe discharge 502 and also limits activity because of exertional 503 desaturation. Clinicians face the difficult dilemma of not $\frac{1}{504}$ performing transplants in patients who are likely to 505 recover from their illness, but also not waiting so long 506 that the patient develops complications or severe 507 deconditioning that precludes transplantation (Fig 3). In 508 the following section, we walk through an algorithm of 509 510 how the authors approach inpatients with CARDS or 511 fibrosis regarding LTx (Fig 4). Although we provide a 512 general roadmap to LTx, it should be recognized that 513 not only is each potential recipient unique, but so too are 514 individual lung transplant programs. Every LTx 515 program must take into consideration their own 516 experience and expertise in undertaking high-risk 517 transplants, while factoring in the adequacy of hospital 518 resources, especially at times of a COVID-19 surge. 519 Lung transplantation is by nature triage medicine in 520 which the likelihood of a successful outcome for 521 522 individual patients needs to be weighed against the 523 societal need in light of an ongoing donor shortage. 524

Does the Patient Have Traditional Contraindications for Transplantation?

528 This question should be considered first, because if 529 patients have a well-established contraindication to 530 transplantation, then the question of lung 531 transplantation as a salvage option can be quickly laid to 532 rest. Absolute medical contraindications include active 533 or recent malignancy (minimum 2-year disease-free 534 interval in cancer with a low likelihood of recurrence, 535 although a 5-year interval is preferred), significant chest 536 537 wall deformity, uncorrectable bleeding diathesis, 538 BMI <17 or >35, or untreatable major organ 539 dysfunction (cardiac, liver disease).⁵ Irreversible 540 neurologic dysfunction represents an absolute 541 contraindication to transplantation. Establishing 542 neurologic status can be difficult in unstable patients 543 who develop marked hypoxemia or hemodynamic 544 instability when not sedated. Other contraindications to 545 transplantation include inability to follow a complex 546 medical regimen, active substance abuse before illness 547 548 (alcohol, illicit or prescription drugs, nicotine), and 549 inadequate social (no postoperative caregiver) or 550 financial support. Although patients may have apparent

chestjournal.org

487

525

526




Figure 4 – Algorithm for potential diagnostic approach to evaluation of inpatient lung transplant candidates with COVID-19. *Adequate time to recovery should consider the individual clinical situation of the patient and must weigh the likelihood of recovery against the risk of development of qui complications that may be fatal without transplantation.

604 605

[■ # ■ CHEST ■ 2021]

661 any residual end-organ dysfunction needs to be ruled 662 out as part of the standard transplant evaluation, 663 because these need to be factored into the patient's 664 overall transplant candidacy. In general in the United 665 States, insurance coverage is required for adequate 666 financial support to proceed with transplantation. 667 Advanced age also represents a contraindication for 668 transplantation. In general, patients being evaluated for 669 LTx who require advanced life support and are in the 670 midst of a prolonged hospitalization should be younger 671 than age 65, although exceptionally robust individuals 672 673 older than this can be considered on a case-by-case 674 basis. The age criteria provided here are somewhat 675 arbitrary, but are generally agreed on for post-COVID 676 LTx given the relative lack of experience with this 677 indication. As the experience with post-COVID 678 transplantation grows, perhaps the acceptable age range 679 will grow as well. 680

681 In general, all efforts should be made to wake patients up 682 before transplantation to obtain consent for the 683 procedure, provide education, assess interest, and engage 684 them in active rehabilitation. If mechanical ventilation 685 and sedation requirements preclude mobilization and 686 rehabilitation, then ECMO support should be strongly 687 considered. All patients and their caregivers should 688 undergo rigorous LTx education and evaluation by a 689 multidisciplinary care team before transplantation. 690 691

Is the Patient's Lung Injury Irreversible?

693 This is often a particularly difficult question to answer 694 and requires the best judgment of the lung transplant 695 team. Patients should receive appropriate standard-of-696 care medical therapy for their COVID-19 infection to 697 optimize the chances for recovery with adequate time 698 allowed for lung recovery. Best clinical practices 699 700 regarding lung protective ventilation and negative fluid 701 balance are essential to prevent potentiation of lung 702 injury. Although arbitrary, a minimum of 4 weeks' time 703 for recovery has been suggested in the medical literature, 704 unless a life-threatening complication that cannot be 705 managed without LTx arises earlier.^{21,22} The authors 706 agree that 4 weeks is considered an absolute minimum, 707 and more often wait for 8+ weeks before seriously 708 considering transplantation. Review of CT imaging may 709 be helpful as well. Findings suggestive of irreversible 710 711 change include traction bronchiectasis and subpleural 712 fibrosis. Anecdotally, we have seen cases with CT 713 evidence of "fibrosis" that has subsequently improved. 714 On the other end of the spectrum, ground-glass 715 infiltrates are commonly encountered early on and are

716 typically due to an alveolar-filling process and hence 717 regarded as potentially reversible. However, this 718 radiographic pattern can also be attributable to early 719 "fine fibrosis," which should be suspected in patients 720 who are further out, especially if seen in the context of 721 traction bronchiectasis or bronchiolectasis. If evidence of 722 organizing pneumonia is present on CT scan, a trial of 723 corticosteroids and possibly azithromycin is reasonable. 724 CT scanning is also useful in assessing for other 725 potentially treatable causes, including pulmonary edema, 726 pleural disease, and bacterial pneumonia. Nosocomial 727 infection is a potential cause of ongoing lung 728 729 dysfunction as well and should be assessed for and 730 treated before making a determination of irreversible 731 lung disease. Multidrug-resistant bacterial infections 732 were noted to complicate the course of many reported 733 patients who underwent transplantation for CARDS, 734 and they likely contributed to the irreversible lung 735 damage they developed.²² 736

Has the Patient Cleared Their COVID-19 Infection?

One major concern with transplantation for patients 741 742 with COVID-19 is the potential impact of lingering 743 active virus. Even a small inoculum of residual viable 744 virus could have potentially devastating consequences, 745 especially in the context of profound 746 immunosuppression typically employed in the early 747 posttransplantation period. With unbridled viral 748 proliferation, COVID-19 could result in acute lung 749 injury, thereby mimicking and perhaps being 750 misdiagnosed as primary graft dysfunction, and thus 751 jeopardizing the patient's outcome. To our knowledge, 752 this concern has not been realized since transplant 753 programs have taken a conservative approach for the 754 patients receiving transplants thus far.^{21,22} The diagnosis 755 of COVID-19 is most commonly established with real- 756 757 time polymerase chain reaction (rt-PCR) testing to 758 detect COVID-19 RNA.²³ Testing is generally 759 performed on upper respiratory tract samples, although 760 lower respiratory tract samples have a higher viral load 761 and are less likely to yield a false negative result.²³ 762 Having a positive rt-PCR result does not necessarily 763 translate into having actively replicating virus, because 764 RNA from viral fragments may still yield a positive rt-765 PCR. Unfortunately no test aside from viral culture can 766 establish the presence of active virus; however, 767 performance of viral culture is not widely available and 768 769 presents infection control issues.²⁴ Data suggest that 770 immunocompetent patients affected with severe or

692

737

738

739

771 critical disease do not have replication-competent virus 772 20 days after symptom onset; however, severely 773 immunocompromised patients may continue to harbor 774 active virus for significantly longer periods.^{25,26} The 775 prolonged harboring of active virus has potential 776 implications in patients with preexisting ILD 777 exacerbated by COVID-19 who have been managed with 778 chronic immunosuppression. It is also conceivable that 779 persistent virus may be fostered by therapy with 780 corticosteroids or immunomodulators such as 781 tocilizumab. As such, a cautious approach to confirming 782 783 clearance of COVID-19 is warranted. Bharat and 784 colleagues²¹ advocated for two negative rt-PCR tests, 785 obtained at least 24 hours apart, from BAL samples in 786 intubated patients before proceeding with LTx. For 787 patients with no tracheostomy or endotracheal tube, two 788 negative upper respiratory tract rt-PCR tests obtained at 789 least 24 hours apart would be the minimum threshold 790 the authors would require to proceed with LTx.²² 791 Because of persistent positive testing, this approach may 792 result in delays in transplantation, but it seems to be a 793 reasonable albeit conservative approach to adopt until 794 further data are available on this issue. 795

Is the Patient Physically Conditioned Enoughfor Transplantation?

800 Most patients with critical COVID-19 will have endured 801 prolonged hospitalization and immobilization, 802 compromised nutritional status from critical illness, and 803 treatment with corticosteroids and neuromuscular 804 blockade, all of which predispose to critical illness 805 polyneuropathy/myopathy and marked deconditioning. 806 Before transplantation, every effort should be made to 807 808 optimize nutritional status and achieve a wakeful, 809 interactive state in which patients can participate 810 meaningfully in the transplantation process and 811 rehabilitation. ECMO support may be required to 812 achieve these goals. In exceptional circumstances, a 813 patient with a normal baseline functional status and 814 good potential for recovery post-LTx whose pulmonary 815 status precludes rehabilitation before transplantation 816 could be considered. Whether rehabilitation potential 817 and frailty present a contraindication to LTx must be 818 interpreted in the context of the patient's global clinical 819 picture and must rely on the clinical judgment of the 820 821 multidisciplinary transplant team. In addition to their 822 physical functional ability, their mental resilience is 823 equally important in withstanding the acute 824 psychological stress of transplantation, as well as the 825 long-term commitment to a strict medical regimen. This is especially difficult for patients who were well before their COVID-19 infection and who have not had the time to accept or adapt psychologically to their new reality.

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

Should Dual Organ Transplantation Be Considered?

The experience with dual organ transplantation for COVID-19 patients is limited. Acute kidney injury (AKI) is estimated to occur in approximately 35% of patients hospitalized with COVID-19, with 12% to 15% requiring renal replacement therapy.^{27,28} Mechanical ventilation is a risk factor for severe AKI. Given the potential reversibility of AKI in COVID-19, the appropriateness of proceeding with renal transplantation in this setting is questionable. Some centers have elected to pursue LTX in patients with COVID-19 complicated by AKI requiring renal replacement therapy who were deemed to have a high likelihood of renal recovery. A lung-kidney transplantation has been performed in a patient with lung and renal failure deemed irreversible.²⁹ One heartlung transplant for COVID-19 in a patient with preexisting cardiomyopathy has been reported.³⁰ To our knowledge, no lung-liver transplantations for COVID-19 have been performed as of yet. Although it is possible that dual organ transplantation could be entertained in the future for highly select candidates, at this time, the authors believe that multi-organ dysfunction should preclude candidacy for LTx in most candidates.

Are There Other Issues Specific to COVID-19 to Consider When Performing a Transplantation?

Given that the LTx recipient will be tested for and 864 865 proven clear of COVID-19 infection before 866 transplantation, the operation need not be performed in 867 a negative-pressure environment. Surgical teams may 868 consider wearing N-95 or equivalent masks and eye 869 protection in addition to standard gown and gloves. 870 Bilateral lung transplantation for COVID-19 has been 871 recommended, because many patients develop 872 significant pulmonary hypertension.^{23,24} Additionally, 873 explants from COVID-19 LTX recipients revealed 874 cavitary areas of pneumonia that could serve as a nidus 875 of infection if a single-lung transplantation was 876 performed.²³ Single-lung transplantation can be 877 considered on a case-by-case basis, even in the presence 878 879 of pulmonary hypertension, especially in patients who 880 are in dire straits with a short window to receive a

796

881 transplant. There may be added theoretic attraction to 882 single-lung transplants, because in some patients this 883 could serve as a "bridge to recovery" of the remaining 884 native lung. Intraoperatively, surgical teams should be 885 prepared for bleeding given the likelihood of pleural 886 adhesions and platelets dysfunction in patients managed 887 with preoperative ECMO support.²⁴ Transplant centers 888 undertaking these cases should be experienced in high-889 acuity transplantation, with robust resources for 890 extracorporeal support and postoperative rehabilitation. 891 892 Our collective experience in performing transplantation 893 in these patients is that their course and risk of specific 894 posttransplantation complications, pulmonary or 895 extrapulmonary, such as acute kidney injury, is no 896 different from that of a general transplant population. 897 This is likely because of these patients being closely 898 vetted for end-organ dysfunction before acceptance. 899

Case 1 Follow-up

900

901

914

915

902 The patient was treated with a course of corticosteroids 903 and completed pulmonary rehabilitation. On follow-up 904 6 months after his initial hospitalization, his FVC had 905 increased by approximately 100 mL to 1.9 L 906 (50% predicted), and his 6MWT had increased by 75 m 907 to 316 m, with decreased need for supplemental oxygen. 908 He felt less dyspneic with activities of daily living. The 909 decision was made to continue rehabilitation and follow-910 up in several months, but to defer initiation of a lung 911 transplant evaluation and assess for ongoing 912 improvement. 913

Case 2 Follow-up

916 In the setting of no significant clinical improvement 917 despite maximum respiratory support, the patient 918 underwent an expedited lung transplant evaluation. 919 After 10 weeks in the hospital, 7 of which were on 920 venous-venous ECMO and mechanical ventilation, she 921 received a bilateral lung transplant. Of note, she had two 922 negative COVID swabs and cleared COVID precautions 923 924 per the hospital epidemiology team before being listed 925 for transplantation. She had a full recovery with minimal 926 complications, and on postoperative day 16 was 927 discharged to an acute rehabilitation facility without any 928 subsequent oxygen needs. 929

930 931 Conclusion

932 COVID-19 can result in severe, irreversible lung injury.
933 In these cases, LTx may represent the only viable
934 therapeutic option, albeit in a very small, highly select
935 group of patients. This patient population presents a

number of unique challenges for providers that require 936 careful consideration. Likely COVID-19-associated lung 937 938 disease will impact the field of ILD and LTx for years to 939 come. Further study is required to determine the natural 940 history of COVID-19-related lung disease. Questions to 941 be addressed through future research include which 942 patients are likely to fully recover, who will be left with 943 residual lung injury, and who will progress to develop 944 persistent or progressive fibrosis, requiring transplant 945 consideration. Further study is also required to 946 determine whether outcomes from LTx for COVID are 947 equivalent to other indications and whether these 948 949 patients are at risk for unique post-LTx complications, 950 including VTE and neurocognitive issues. An 951 International Registry of COVID-related lung 952 transplants could provide a foundation for expediting 953 the answers to these and other emerging questions in 954 this nascent area. 955

Acknowledgments

Financial/nonfinancial disclosures: None declared.

References

- 960 1. World Health Organization. WHO Coronavirus (COVID-19) 961 Dashboard. https://covid19.who.int/. Accessed May 3, 2021. 962 Wu Z, McGoogan JM. Characteristics of and important lessons from 2. the coronavirus disease 2019 (COVID-19) outbreak in China: 963 summary of a report of 72,314 cases from The Chinese Center for 964 Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. 965 3. Armstrong RA, Kane AD, Kursumovic E, Oglesby FC, Cook TM. 966 Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational 967 studies. Anaesthesia. 2021;76:537-548. 968 4. U.S. Department of Health & Human Services. Organ Procurement 969 and Transplantation Network. https://optn.transplant.hrsa.gov/data 970 view-data-reports/build-advanced/. Accessed May 12, 2021. 5. Weill D, Benden C, Corris PA, et al. A consensus document for the 971 selection of lung transplant candidate: 2014-An update from the 972 Pulmonary Transplantation Council of the International Society for 973 Heart and Lung Transplantation. J Heart Lung Trans. 2015;34(1):1-974 15. 6. Guler SA, Ebner L, Aubry-Beigelman C, et al. Pulmonary function 975 and radiological features 4 months after COVID-19: first results 976 from the national prospective observational Swiss COVID-19 lung 977 study. Eur Respir J. 2021;57:2003690.
- Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. *Radiology*. 2021;299(1): 979 E177-E186. 980
- Gonzalez J, Benitez ID, Carmona P, et al. Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. *Chest.* 2021;160(1):187-198.
 982
- Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies [Published online ahead of print August 20, 2020]. *Pulm Med*. 2020. https://doi.org/10.1155/2020/6175964.
- McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? *Am J Physiol Lung Cell Mol Physiol*. 2021;320(2): 987 1257-1265. 988
- Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. *Lung India*. 2021;38:S41-S47.

956

957

958

991	12. Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung
992	abnormalities detected incidentally on CT: a position paper from the
	Fleischner Society. Lancet Respir Med. 2020;8(7):726-737.

- 13. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease: an observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799-806.
- 996 14. Vadasz I, Husain-Syed F, Dorfmuller P, Roller FC, Tello K. Severe organizing pneumonia following COVID-19. *Thorax*. 2021;76(2): 201-204.
- 998 15. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID999 19: the potential role for anti-fibrotic therapy. *Lancet Respir Med.*2020;8:807-815.
- 16. National Institutes of Health Clinical Center. Treatment With Pirfenidone for COVID-19 Related Severe ARDS. NCT04653831. ClinicalTrials.gov. National Institutes of Health; 2020. Updated December 4, 2020, https://clinicaltrials.gov/ct2/show/NCT04653831

 1003
 December 4, 2020, https://clinicaltrials.gov/ct2/show/NCT04653831

 1004
 June 2, 2021.
- 1005 17. National Institutes of Health Clinical Center. Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19 (FIBRO-COVID). NCT04607928. ClinicalTrials.gov. National Institutes of Health; 2020. Updated November 5, 2020, https:// clinicaltrials.gov/ct2/show/NCT04607928?
- 1009 term=pirfenidone&cond=Covid19&draw=2&rank=2. Accessed June 2, 2021.
- 1010 (J. Mational Institutes of Health Clinical Center. Pirfenidone vs.
 1011 Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19
 1012 Pneumonia (PINCER). NCT04856111. ClinicalTrials.gov. National Institutes of Health; 2021. Updated April 28, 2021, https:// clinicaltrials.gov/ct2/show/NCT04856111?
- 1014term=pirfenidone&cond=Covid19&draw=2&rank=3. Accessed1015June 2, 2021.
- 1016
 19. National Institutes of Health Clinical Center. The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19 (ENDCOV-I).
 1018 NCT04619680. ClinicalTrials.gov. National Institutes of Health; 2020. Updated April 1, 2021, https://clinicaltrials.gov/ct2/show/ NCT04619680?term=nintedanib&cond=Covid19&draw=2
 1020 & & trank=4. Accessed June 2, 2021.
- 1021
- 1022
- 1023
- 1024

- Matsuishi Y, Mathis BJ, Shimojo N, Subrina J, Okubo N, Inoue Y. Severe COVID-19 infection associated with endothelial dysfunction induces multiple organ dysfunction: a review of therapeutic interventions. *Biomedicines*. 2021;9(3):279.
- Bharat A, Querrey M, Markov NS, et al. Lung transplantation for patients with severe COVID-19. *Sci Transl Med.* 2020;12(574): eabe4282.
- 22. Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. *Lancet Respir Med.* 2021;9: 487-497.
- 23. Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021;538:226-230.
- Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious potential assessment: a systematic review [Published online ahead of print December 3, 2020]. *Clin Infect Dis.* 2020. https://doi.org/10.1093/cid/ciaa1764.
- 25. Centers for Disease Control and Prevention. Interim Guidance on Ending Isolation and Precautions for Adults with COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation. html. Accessed May 20, 2021.
- Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586.
- 27. Hirsch JS, NG JH, Ross DW, et al. Acute kidney injured in patients hospitalized with COVID-19. *Kidney Int.* 2020;98(1):209.
- Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Azy Z. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. *Clin J Am Soc Nephrol.* 2020;16(1):14.
- 29. Stanford Medicine News Center. Double transplant at Stanford saves life of critically ill COVID-19 patient. https://med.stanford.edu/news/all-news/2021/03/double-transplant-saves-life-of-critically-ill-covid-19-patient.html. Accessed June 7, 2021.
- 30. Vanderbilt University Medical Center. COVID patient's heart-lung transplant is world's first. https://news.vumc.org/2020/10/08/covid-patients-heart-lung-transplant-is-worlds-first/. Accessed June 7, 2021.

1058

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050